-+ 0.00%
-+ 0.00%
-+ 0.00%
Palisade Bio presents PALI-2108 Phase 1b data showing clinical response in all five ulcerative colitis patients
Share
Listen to the news
Palisade Bio presents PALI-2108 Phase 1b data showing clinical response in all five ulcerative colitis patients
  • Palisade Bio targets a fourth-quarter 2027 Phase 2 primary efficacy readout for PALI-2108 in ulcerative colitis.
  • A Phase 2 primary efficacy readout in Crohn's disease is targeted for the first quarter of 2028.
  • In a five-patient, open-label ulcerative colitis study, all patients achieved clinical response by day seven; two achieved clinical remission.
  • Two of five patients achieved endoscopic remission in a 14-day, open-label Crohn's disease study.
  • The Crohn's disease cohort had no serious adverse events or treatment discontinuations; all adverse events were mild.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending